Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Technology for treating lupus erythematosus by DC (dendritic cell) and Treg (T regulator cell)

A lupus erythematosus and cell therapy technology, applied in the medical field, can solve problems such as dysfunction, decreased human immunity, and patients' susceptibility to other diseases, so as to achieve good health, prevent autoimmunity, and normalize the human immune system

Active Publication Date: 2014-04-16
CHANGSHA YINGRUN BIOTECH
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] 1. The treatment of comprehensive tissue and organ diseases is caused by lupus erythematosus, and their treatment can only relieve symptoms, treat the symptoms but not the root cause, and long-term treatment will form drug dependence and resistance
[0007] 2. Adrenal cortex hormones can cause dysfunction and dysfunction of the human body
[0008] 3. While immunosuppressant is being treated, it will cause the decline of human immunity, and patients are prone to other diseases
[0009] 4. At the same time, the long-term use of drugs makes the body in a sub-health state caused by drugs for a long time, and the drug and medical expenses are high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Technology for treating lupus erythematosus by DC (dendritic cell) and Treg (T regulator cell)
  • Technology for treating lupus erythematosus by DC (dendritic cell) and Treg (T regulator cell)
  • Technology for treating lupus erythematosus by DC (dendritic cell) and Treg (T regulator cell)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] A technique for treating lupus erythematosus with DC and Treg cells, including the following steps:

[0033] (1) Collect 100ml of peripheral venous blood from patients with lupus erythematosus during the non-onset period;

[0034] (2) Mononuclear cells are isolated from blood by density gradient separation;

[0035] The separation steps are as follows:

[0036] 1) Take 100ml of anticoagulated blood, and add the blood into four 50ml sterile centrifuge tubes;

[0037] 2) Centrifuge at 300g for 10min. After centrifugation, transfer all the upper plasma to two new sterile centrifuge tubes, inactivate it in a water bath at 56°C for 30min, and then centrifuge at 400g for 10min to collect the upper yellow liquid (Poor platelet plasma). Platelet Plasma, PPP), stored at 4°C for later use;

[0038] 3) Add physiological saline for injection to the four centrifuge tubes containing blood cells in the lower layer until the mixed solution is 30ml in each tube, and mix with a pipett...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A technology for treating lupus erythematosus by a DC (dendritic cell) and a Treg (T regulator cell ) comprises the following steps: (1), peripheral venous blood is collected from a non-disease period of a lupus erythematosus patient; (2), a mononuclear cell is obtained through separation from the blood with a density gradient separation method; (3), the mononuclear cell is cultured in a culture container for 2 h by a culture solution, then a supernatant is poured into a new culture container, an adherent cell in the original culture container is used for being differentiated into the DC, and a suspension cell in the new container is differentiated into the Treg; (4), a special antigen is added into the DC differentiating culture solution for DC functionalization treatment; (5), DC and Treg are mixed for culturing and amplification; and (6), an amplified cell is cleaned by normal saline and is subjected to intravenous drip for reinfusion treatment of the lupus erythematosus. According to the technology, a cellular immunity technology is adopted to recover a normal condition of an immune system, and furthermore, the DC and the Treg belong to human body cells and can remain in the body for a long period, so that long-term treatment effect is achieved.

Description

technical field [0001] The invention relates to the medical field, in particular to a technique for treating lupus erythematosus with DC and Treg cells. Background technique [0002] Lupus erythematosus is one of the typical autoimmune connective tissue diseases with systemic, chronic progressive recurrent attacks and remissions. The disease is more frequent in women and can invade multiple organs of the body. The development of immunology technology enables timely diagnosis and treatment of early mild and atypical cases. Therefore, except for a few severe cases or damage to important organs, some cases can be relieved spontaneously, and some cases only appear once. Sexual seizures, after several months or a short course of disease, the symptoms disappear completely. In terms of treatment, the ten-year survival rate of lupus patients has reached 85% due to the rational use of corticosteroid hormones, immunomodulators, plasma exchange therapy, and integration of traditional ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/14A61K39/00A61P37/02A61K35/15
Inventor 易银沙张万明朱海强邹义洲许澎李娜刘彩云袁炳秋吴小宁
Owner CHANGSHA YINGRUN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products